1-(indan-5-ylamino)-4-(4-pyridylmethyl)phthalazine | 325781-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(indan-5-ylamino)-4-(4-pyridylmethyl)phthalazine
• 英文别名: 1-(indan-5-ylamino)-4-(pyridin-4-ylmethyl)phthalazine；N-(2,3-dihydro-1H-inden-5-yl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
• CAS: 325781-25-7
• 化学式: C₂₃H₂₀N₄
• 分子量: 352.439
• InChiKey: CYVOMIZSBADRDI-UHFFFAOYSA-N

物化性质

• 沸点：
  599.2±50.0 °C(Predicted)
• 密度：
  1.268±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY<br/>[FR] PYRIDAZINES SUBSTITUEES ET PYRIDAZINES FUSIONNEES POSSEDANT UNE ACTIVITE D'NHIBITION DE L'ANGIOGENESE
  申请人：BAYER AG

  公开号：WO2001010859A1

  公开（公告）日：2001-02-15

  Substituted and fused pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R?1 and R2¿ may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

  具有抑制血管生成活性的取代和融合吡啶并噻唑化合物，其具有广义结构式（I），其中包含A，B，D，E和L的环是含氮杂环；X和Y基团可以是各种定义的连接单元之一；R?1和R2¿可以是定义独立的取代基，或者一起可以是定义环的桥；环J可以是芳香族，吡啶基或环烷基团；G基团可以是各种定义的取代基。还公开了含有这些材料的制药组合物以及使用这些材料治疗具有异常血管生成或高渗透性过程的哺乳动物的方法。
• CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：Eisai Co., Ltd.

  公开号：EP1216980A1

  公开（公告）日：2002-06-26

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin-resistant improver, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula (I), a salt thereof, an ester thereof or a hydrate of them. In the formula, R1 represents hydrogen atom, hydroxyl group or a C1-6 alkyl group etc. which may have one or more substituents; L represents a single or double bond or a C1-6 alkylene group etc. which may have one or more substituents; M represents a single bond or a C1-6 alkylene group etc. which may have one or more substituents; T represents a single bond or a C1-3 alkylene group which may have one or more substituents; W represents carboxyl group or a group represented by the formula -CON(Rw1)Rw2 (wherein Rw1 and Rw2 are the same as or different from each other and each represents hydrogen atom, formyl group etc.) etc.; represents a single or double bond; X represents oxygen atom or a C2-6 alkenylene group etc. which may have one or more substituents; Y represents a C5-12 aromatic hydrocarbon group etc. which may have one or more substituents and which may have one or more heteroatoms; and ring Z represents a C5-6 aromatic hydrocarbon group which may have 0 to 4 substituents and which may have one or more heteroatoms.

  本发明提供了一种新型羧酸化合物、其盐或它们的水合物，可用作胰岛素抗性改进剂，以及包含该化合物作为活性成分的药物。也就是说，本发明提供了由下式（I）代表的羧酸化合物、其盐、酯或它们的水合物。 式中，R1 代表氢原子、羟基或 C1-6 烷基等，可有一个或多个取代基；L 代表单键或双键或 C1-6 亚烷基等，可有一个或多个取代基；M 代表单键或 C1-6 亚烷基等，可有一个或多个取代基。W 代表羧基或由式-CON(Rw1)Rw2 所代表的基团（其中 Rw1 和 Rw2 彼此相同或不同，且各自代表氢原子、甲酰基等）等。)等表示的基团；代表单键或双键；X 代表氧原子或 C2-6 烯基等，可有一个或多个取代基；Y 代表 C5-12 芳烃基等，可有一个或多个取代基，可有一个或多个杂原子；环 Z 代表 C5-6 芳烃基，可有 0 至 4 个取代基，可有一个或多个杂原子。
• SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：Bayer Corporation

  公开号：EP1208096B1

  公开（公告）日：2004-04-28
• US6903101B1
  申请人：——

  公开号：US6903101B1

  公开（公告）日：2005-06-07
• US6884821B1
  申请人：——

  公开号：US6884821B1

  公开（公告）日：2005-04-26